Proposal to list laboratory equipment and consumables supplied by In Vitro Technologies NZ Pty Limited
Pharmac is seeking feedback on a proposal to list a range of medical devices in Part III of Section H of the Pharmaceutical Schedule.
What we’re proposing
Pharmac is seeking feedback on a proposal to list laboratory equipment and consumables supplied by In Vitro Technologies NZ Pty Limited (“In Vitro”) in Part III of Section H of the Pharmaceutical Schedule from 1 April 2022 through a non-exclusive provisional agreement.
Consultation closes at 4pm Monday 14 February 2022 and feedback can be emailed to email@example.com.
What would the effect be?
From 1 April 2022 laboratory equipment and consumables supplied by In Vitro would be listed under a proposed national agreement (“Agreement”) that all DHBs may purchase under, subject to consultation and approval by Pharmac’s Board or delegate.
The Agreement would not be for sole supply and DHBs can continue to purchase other suppliers’ brands of laboratory equipment and consumables.
The Agreement would supersede any existing DHB agreements with In Vitro for the medical devices included in the Agreement. Any medical device listed in the Agreement and purchased by a DHB would be in accordance with the terms and conditions, including price, stated in the Agreement effective from the date of listing in the Pharmaceutical Schedule.
Pricing for the medical devices in the Agreement, subject to any prior termination of the Agreement, would not be increased without prior consultation and approval by Pharmac.
Who we think will be interested
- DHB clinical staff in a range of different clinical settings including but not limited to:
- Laboratory managers, scientists, technicians and other laboratory staff
- Clinical engineers and maintenance services
- Clinical product evaluators
- Procurement officers and supply chain personnel
- Suppliers and wholesalers
About the medical devices
The laboratory equipment and consumables category includes medical devices used in the collection, receipt, preparation and analysis of human biological material for the purpose of supporting patient diagnosis, management and treatment.
Why we’re proposing this
The RFP was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
PHARMAC has been working with suppliers who responded to the RFP and whose proposals were progressed to contract negotiation to seek provisional agreements.
We expect to consult on further provisional agreements with suppliers of laboratory equipment and consumables throughout 2022.
Details about our proposal
Pharmac has entered into a provisional agreement with In Vitro for the supply of laboratory equipment and consumables.
The proposal would result in 674 laboratory equipment and consumable products being listed on the Pharmaceutical Schedule. The proposal would result in Pharmaceutical Schedule listings of the following brands of medical devices:
Further information, including pricing and contractual details, has been provided to DHB procurement personnel. Clinicians interested in further detail on what this means for their DHB should engage with their procurement teams.
To provide feedback
Send us an email: firstname.lastname@example.org by 4pm 14 February 2022.
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Your feedback may be shared
Feedback we receive is subject to the Official Information Act 1982 (OIA). Please be aware that we may need to share your feedback, including your identity, in response to an OIA request. This applies to anyone providing feedback, whether they are providing feedback themselves or for an organisation, in a personal or professional capacity.
We can only keep feedback confidential as allowed under the OIA and other related laws. If you want any part of your feedback treated as confidential, you need to tell us. Please let us know if you want to keep part of your feedback confidential, and why. Is it commercially sensitive, confidential or proprietary, or personal information? Clearly state this and tell us which parts of your feedback you want to keep confidential for these reasons. We will consider your request under our OIA requirements.